Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells

Keyphrases

• Small Interfering RNA (siRNA) 100%
• Cancer Therapy 100%
• Nanocapsules 100%
• Nanoencapsulation 100%
• Malignant Cancer 100%
• Small Molecule Drugs 100%
• Nucleic Acids 50%
• Prostate Cancer Cells 50%
• Drug Delivery 50%
• Cancer Cells 50%
• Inhibitor-2 50%
• Catalytic Subunit 50%
• Dimethylamino 50%
• Tenfibgen 50%
• Benzimidazole 50%
• Cargo 50%
• Nuclear factor-κB p65 50%
• Small Molecule Acid 50%
• CK2 Inhibition 50%
• Strong Potential 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Small Interfering RNA 100%
• Nanocapsule 50%
• Prostate Cancer 25%
• Phosphotransferase 25%
• Nucleic Acid 25%
• Immunoglobulin Enhancer Binding Protein 25%
• Benzimidazole 25%
• 4,5,6,7 Tetrabromo 2 Dimethylamino 1h Benzimidazole 25%